{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:58:53Z","timestamp":1783763933324,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH NIEHS","award":["F32ES028576 (AF)"],"award-info":[{"award-number":["F32ES028576 (AF)"]}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline plc","doi-asserted-by":"crossref","award":["SUMMIT; HZC113782\/NCT01313676"],"award-info":[{"award-number":["SUMMIT; HZC113782\/NCT01313676"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12931-019-1059-1","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T13:24:15Z","timestamp":1557321855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6089-366X","authenticated-orcid":false,"given":"Ashraf","family":"Fawzy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Cowans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Crim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia N.","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,8]]},"reference":[{"key":"1059_CR1","unstructured":"WHO. World health statistics 2008. Geneva: World Health Organization; 2008."},{"issue":"46","key":"1059_CR2","doi-asserted-by":"publisher","first-page":"5s","DOI":"10.1183\/09031936.03.00004603a","volume":"22","author":"ED Oudijk","year":"2003","unstructured":"Oudijk ED, Lammers JJ, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(46 suppl):5s\u201313s.","journal-title":"Eur Respir J"},{"issue":"5","key":"1059_CR3","doi-asserted-by":"publisher","first-page":"e37483","DOI":"10.1371\/journal.pone.0037483","volume":"7","author":"A Agust\u00ed","year":"2012","unstructured":"Agust\u00ed A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.","journal-title":"PLoS One"},{"issue":"112","key":"1059_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1183\/09059180.00000609","volume":"18","author":"A Lacoma","year":"2009","unstructured":"Lacoma A, Prat C, Andreo F, Dominguez J. Biomarkers in the management of COPD. Eur Respir Rev. 2009;18(112):96\u2013104.","journal-title":"Eur Respir Rev"},{"issue":"19","key":"1059_CR5","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.1915.02580190006002","volume":"65","author":"W Duke","year":"1915","unstructured":"Duke W. Variation in the platelet count: its cause and clinical significance. J Am Med Assoc. 1915;65(19):1600\u20137.","journal-title":"J Am Med Assoc"},{"issue":"3","key":"1059_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/MBC.0b013e32833449c9","volume":"21","author":"G Aliberti","year":"2010","unstructured":"Aliberti G, Proietta M, Pulignano I, Del Porto F, Tammeo A, Trappolini M. Association between fibrinogen plasma levels and platelet counts in an outpatient population and in patients with coronary heart disease. Blood Coagul Fibrinolysis. 2010;21(3):216\u201320.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"1059_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.15326\/jcopdf.2.1.2014.0138","volume":"2","author":"DM Mannino","year":"2015","unstructured":"Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. Chron Obstruct Pulmon Dis. 2015;2(1):23.","journal-title":"Chron Obstruct Pulmon Dis"},{"issue":"3","key":"1059_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3109\/15412555.2012.752807","volume":"10","author":"R Casaburi","year":"2013","unstructured":"Casaburi R, Celli B, Crapo J, et al. The COPD biomarker qualification consortium (CBQC). COPD: J Chron Obstruct Pulmon Dis. 2013;10(3):367\u201377.","journal-title":"COPD: J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"1059_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.annepidem.2017.02.001","volume":"27","author":"GC Kabat","year":"2017","unstructured":"Kabat GC, Kim MY, Verma AK, et al. Platelet count and total and cause-specific mortality in the Women's Health Initiative. Ann Epidemiol. 2017;27(4):274\u201380.","journal-title":"Ann Epidemiol"},{"issue":"5","key":"1059_CR10","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3324\/haematol.2013.101949","volume":"99","author":"P Msaouel","year":"2014","unstructured":"Msaouel P, Lam AP, Gundabolu K, et al. Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica. 2014;99(5):930\u20136.","journal-title":"Haematologica"},{"issue":"13","key":"1059_CR11","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2015-06-654764","volume":"126","author":"M-T Tsai","year":"2015","unstructured":"Tsai M-T, Chen Y-T, Lin C-H, Huang T-P, Tarng D-C. U-shaped mortality curve associated with platelet count among older people: a community-based cohort study. Blood. 2015;126(13):1633\u20135.","journal-title":"Blood"},{"issue":"3","key":"1059_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1538-7836.2008.03267.x","volume":"7","author":"JG van der Bom","year":"2009","unstructured":"van der Bom JG, Heckbert SR, Lumley T, et al. Platelet count and the risk for thrombosis and death in the elderly. J Thromb Haemost. 2009;7(3):399\u2013405.","journal-title":"J Thromb Haemost"},{"key":"1059_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.thromres.2016.08.012","volume":"148","author":"PJ Vinholt","year":"2016","unstructured":"Vinholt PJ, Hvas A-M, Frederiksen H, Bathum L, J\u00f8rgensen MK, Nybo M. Platelet count is associated with cardiovascular disease, cancer and mortality: a population-based cohort study. Thromb Res. 2016;148:136\u201342.","journal-title":"Thromb Res"},{"issue":"12","key":"1059_CR14","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1182\/blood-2016-01-692814","volume":"127","author":"M Bonaccio","year":"2016","unstructured":"Bonaccio M, Di Castelnuovo A, Costanzo S, et al. Age-sex\u2013specific ranges of platelet count and all-cause mortality: prospective findings from the MOLI-SANI study. Blood. 2016;127(12):1614\u20136.","journal-title":"Blood"},{"key":"1059_CR15","doi-asserted-by":"publisher","first-page":"781857","DOI":"10.1155\/2014\/781857","volume":"2014","author":"K Ghoshal","year":"2014","unstructured":"Ghoshal K, Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. TheScientificWorldJournal. 2014;2014:781857.","journal-title":"TheScientificWorldJournal"},{"issue":"6","key":"1059_CR16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3109\/09537104.2011.573887","volume":"22","author":"VR Biljak","year":"2011","unstructured":"Biljak VR, Pancirov D, Cepelak I, Popovic-Grle S, Stjepanovic G, Grubisic TZ. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets. 2011;22(6):466\u201370.","journal-title":"Platelets"},{"issue":"8","key":"1059_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/resp.12143","volume":"18","author":"RT Wang","year":"2013","unstructured":"Wang RT, Li JY, Cao ZG, Li Y. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2013;18(8):1244\u20138.","journal-title":"Respirology"},{"issue":"7","key":"1059_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/thoraxjnl-2013-203996","volume":"69","author":"MT Harrison","year":"2014","unstructured":"Harrison MT, Short P, Williamson PA, Singanayagam A, Chalmers JD, Schembri S. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014;69(7):609\u201315.","journal-title":"Thorax"},{"issue":"5","key":"1059_CR19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5603\/PiAP.2015.0056","volume":"83","author":"MH Rahimi-Rad","year":"2015","unstructured":"Rahimi-Rad MH, Soltani S, Rabieepour M, Rahimirad S. Thrombocytopenia as a marker of outcome in patients with acute exacerbation of chronic obstructive pulmonary disease. Adv Respir Med. 2015;83(5):348\u201351.","journal-title":"Adv Respir Med"},{"issue":"1","key":"1059_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12931-018-0717-z","volume":"19","author":"A Fawzy","year":"2018","unstructured":"Fawzy A, Putcha N, Paulin LM, et al. Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. Respir Res. 2018;19(1):20.","journal-title":"Respir Res"},{"issue":"5","key":"1059_CR21","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1183\/13993003.00399-2016","volume":"47","author":"M Bafadhel","year":"2016","unstructured":"Bafadhel M, Russell RE. Are COPD and cardiovascular disease fundamentally intertwined? Eur respiratory Soc. 2016;47(5):1307\u20139.","journal-title":"Eur respiratory Soc"},{"issue":"5","key":"1059_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1183\/09031936.00087312","volume":"41","author":"J\u00f8rgen Vestbo","year":"2012","unstructured":"Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C, Haumann B, Martinez FJ, Yates J, Newby DE. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013;41(5):1017\u201322.","journal-title":"European Respiratory Journal"},{"issue":"10030","key":"1059_CR23","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","volume":"387","author":"J Vestbo","year":"2016","unstructured":"Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817\u201326.","journal-title":"Lancet"},{"issue":"19","key":"1059_CR24","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1136\/heartjnl-2016-310897","volume":"103","author":"RD Brook","year":"2017","unstructured":"Brook RD, Anderson JA, Calverley PM, et al. Cardiovascular outcomes with an inhaled beta2-agonist\/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017;103(19):1536\u201342.","journal-title":"Heart"},{"issue":"16","key":"1059_CR25","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/sim.1815","volume":"23","author":"P Royston","year":"2004","unstructured":"Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med. 2004;23(16):2509\u201325.","journal-title":"Stat Med"},{"issue":"2","key":"1059_CR26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1161\/01.CIR.84.2.613","volume":"84","author":"E Thaulow","year":"1991","unstructured":"Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation. 1991;84(2):613\u20137.","journal-title":"Circulation"},{"issue":"1","key":"1059_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1465-9921-14-24","volume":"14","author":"R Ferrari","year":"2013","unstructured":"Ferrari R, Tanni SE, Caram LM, Corr\u00eaa C, Corr\u00eaa CR, Godoy I. Three-year follow-up of interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res. 2013;14(1):24.","journal-title":"Respir Res"},{"issue":"10","key":"1059_CR28","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1164\/rccm.201110-1792OC","volume":"185","author":"BR Celli","year":"2012","unstructured":"Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065\u201372.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1059_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1749-6632.2001.tb03534.x","volume":"936","author":"GM Fuller","year":"2001","unstructured":"Fuller GM, Zhang Z. Transcriptional control mechanism of fibrinogen gene expression. Ann NY Acad Sci. 2001;936(1):469\u201379.","journal-title":"Ann NY Acad Sci"},{"issue":"12","key":"1059_CR30","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMra035363","volume":"350","author":"AI Schafer","year":"2004","unstructured":"Schafer AI. Thrombocytosis. N Engl J Med. 2004;350(12):1211\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"1059_CR31","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1113\/jphysiol.2011.225417","volume":"590","author":"KY Stokes","year":"2012","unstructured":"Stokes KY, Granger DN. Platelets: a critical link between inflammation and microvascular dysfunction. J Physiol. 2012;590(5):1023\u201334.","journal-title":"J Physiol"},{"key":"1059_CR32","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2147\/COPD.S67044","volume":"9","author":"SD Shukla","year":"2014","unstructured":"Shukla SD, Sohal SS, Mahmood MQ, Reid D, Muller HK, Walters EH. Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:853.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1059_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/1755-5922.12233","volume":"35","author":"AVK Palur Ramakrishnan","year":"2017","unstructured":"Palur Ramakrishnan AVK, Varghese TP, Vanapalli S, Nair NK, Mingate MD. Platelet activating factor: a potential biomarker in acute coronary syndrome? Cardiovasc Ther. 2017;35(1):64\u201370.","journal-title":"Cardiovasc Ther"},{"issue":"06","key":"1059_CR34","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1160\/TH16-12-0973","volume":"117","author":"G Campo","year":"2017","unstructured":"Campo G, Dalla Sega FV, Pavasini R, et al. Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thromb Haemost. 2017;117(06):1208\u201316.","journal-title":"Thromb Haemost"},{"issue":"2","key":"1059_CR35","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1378\/chest.09-0998","volume":"137","author":"M Mirsaeidi","year":"2010","unstructured":"Mirsaeidi M, Peyrani P, Aliberti S, et al. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest. 2010;137(2):416\u201320.","journal-title":"Chest"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1059-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-019-1059-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1059-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T10:33:17Z","timestamp":1694860397000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-019-1059-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1059"],"URL":"https:\/\/doi.org\/10.1186\/s12931-019-1059-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,8]]},"assertion":[{"value":"31 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by local ethics committees and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AF declares no conflict of interest. JAA, CC and JCY are employees of, and own shares in, GlaxoSmithKline plc. NJC is employed by Veramed Ltd., a Contract Research Organisation undertaking contracted statistical analyses of respiratory studies funded by GlaxoSmithKline plc. RW served as the Chair of the Summit Clinical Endpoint Committee and has received grant support and received consulting fees from GlaxoSmithKline plc during the conduct of the study. He has received grants and consulting fees from AstraZeneca and Boehringer Ingelheim. He has received consulting fees from Contrafect, Pulmonx, Roche, Spiration, Sunovion, Merck, Circassia, Verona, Mylan, Theravance, and Propeller Health unrelated to the submitted work. NNH has participated on advisory boards for GlaxoSmithKline plc, Mylan and AstraZeneca, and has received Research Grants from GlaxoSmithKline plc, AstraZeneca and Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"86"}}